SGLT2i and AF

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Jamschid Sedighi

Justus-Liebig University of Giessen, Giessen (Germany)

5 More presentations in this session

Presentation thumbnail

CONFIDENCE: Results by KDIGO risk category

Doctor M. Vaduganathan (Boston, US)

Presentation thumbnail

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

Professor M. Mamas (Keele, GB)

Presentation thumbnail

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Ms L. Wilson (US)

Presentation thumbnail

STRIDE Outcomes by Sexl

Professor S. Verma (Toronto, CA)

Presentation thumbnail

Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction

Doctor N. Kruger (Boston, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Inflamed atrial tissues of patients with atrial fibrillation are characterized by pro-oxidant and pro-remodeling responses: synergistic inhibition by an SGLT2 inhibitor plus a GLP-1R activation

Congress Presentation

Associations between prediabetes and diabetes mellitus type 2 and incident atrial fibrillation in patients with hypertension; results from the Swedish Primary Care Cardiovascular Database

Congress Presentation

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve indices of atrial cardiomyopathy: a systematic review and meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources